Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.41 |
| ▸ | LMNA | P02545 | 7/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756044 | 0.85 | NR3C2 (0.60) | NR3C2WDR5ALDH1A1LMNAMAPT | |
| SCHEMBL758117 | 0.78 | NR3C2 (0.43) | NR3C2WDR5ALDH1A1LMNAMAPT | |
| SCHEMBL27735521 | 0.74 | WDR5 (0.39) | WDR5ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL27414020 | 0.73 | MAPT (0.42) | ALDH1A1LMNAMAPTGAAMEN1 | |
| SCHEMBL9147151 | 0.73 | CASP6 (0.38) | NR3C2ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL9146981 | 0.72 | L3MBTL1 (0.45) | NR3C2WDR5ALDH1A1LMNAMAPT | |
| SCHEMBL5140408 | 0.72 | NR3C2 (0.41) | NR3C2ALDH1A1LMNAMAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9143208 | 0.71 | L3MBTL1 (0.44) | NR3C2WDR5ALDH1A1LMNAMAPT | |
| SCHEMBL758128 | 0.70 | ALDH1A1 (0.36) | NR3C2ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL757262 | 0.67 | NR3C2 (0.60) | NR3C2WDR5ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998956-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | NR3C2, MC2R, NR3C1 | NR3C2 1/4885WDR5 3339/4885ALDH1A1 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.